Relación entre el antígeno prostático específico y la hiperplasia prostática benigna en pacientes mexicanos. Estudio REPSA

Abstract

AimTo determine the relation between prostate-specific antigen (PSA) and benign prostatic hyperplasia (BPH) using the prostate volume in patients with lower urinary tract symptoms as a hyperplasia marker. Material and methodsThe REPSA study is a multicenter epidemiologic data register on Mexican adult men over 50 years of age that presented with BPH and moderate-to-severe lower urinary tract symptoms defined by the International Prostate Symptom Scale (IPSS). Patients that had active urinary infections, prostatitis, or those diagnosed with prostate cancer were excluded from the study. Prostate volume was determined through ultrasound and serum PSA was measured in each of the patients. ResultsA total of 855 patients were studied (mean age 64.0±8.9 years) and the mean BPH progression time was 3.3±3.1 years. The mean PSA value was 2.1±3.2ng/ml. Erectile dysfunction prevalence was 81.9%. The mean prostate volume was 44.5±26.7mm3. There was a positive correlation between PSA and prostate volume (Pearson correlation coefficient=0.88, P<.01). ConclusionsThere was a positive correlation between PSA levels and prostate volume in Mexican patients presenting with BPH and lower urinary tract symptoms.